Epigenetic Aspects of a New Probiotic Concept—A Pilot Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. Study Design
2.3. Data Collection
2.4. Biochemical Parameters
2.5. Preparation of Dried Blood Spots
2.6. DNA/RNA Extraction
2.7. cDNA Synthesis miRNA and mRNA
2.8. mRNA and miRNA Expression
2.9. Statistical Analysis
3. Results
3.1. Dietary Habits Analysis
3.2. Anthropometric Changes
3.3. Analysis of Lipid Parameter Changes
3.4. Molecular Changes following 12 Weeks of Intervention
3.5. Correlations between Dietary Habits and Anthropometric Data with Selected Epigenetic Markers
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Haththotuwa, R.N.; Wijeyaratne, C.N.; Senarath, U. Worldwide epidemic of obesity. In Obesity and Obstetrics; Elsevier: Amsterdam, The Netherlands, 2020; pp. 3–8. [Google Scholar]
- Sivamaruthi, B.S.; Kesika, P.; Suganthy, N.; Chaiyasut, C. A review on role of microbiome in obesity and antiobesity properties of probiotic supplements. BioMed Res. Int. 2019, 2019, 3291367. [Google Scholar] [CrossRef]
- Geng, J.; Ni, Q.; Sun, W.; Li, L.; Feng, X. The links between gut microbiota and obesity and obesity related diseases. Biomed. Pharmacother. 2022, 147, 112678. [Google Scholar] [CrossRef] [PubMed]
- Cani, P.D.; Van Hul, M. Novel opportunities for next-generation probiotics targeting metabolic syndrome. Curr. Opin. Biotechnol. 2015, 32, 21–27. [Google Scholar] [CrossRef] [PubMed]
- Morovic, W.; Budinoff, C.R. Epigenetics: A new frontier in probiotic research. Trends Microbiol. 2021, 29, 117–126. [Google Scholar] [CrossRef] [PubMed]
- Zhao, Y.; Zeng, Y.; Zeng, D.; Wang, H.; Zhou, M.; Sun, N.; Xin, J.; Khalique, A.; Rajput, D.S.; Pan, K. Probiotics and MicroRNA: Their roles in the host–microbe interactions. Front. Microbiol. 2021, 11, 604462. [Google Scholar] [CrossRef]
- Wang, Q.; Sun, Q.; Wang, J.; Qiu, X.; Qi, R.; Huang, J. Lactobacillus plantarum 299v changes miRNA expression in the intestines of piglets and leads to downregulation of LITAF by regulating ssc-miR-450a. Probiotics Antimicrob. Proteins 2021, 13, 1093–1105. [Google Scholar] [CrossRef] [PubMed]
- Vähämiko, S.; Laiho, A.; Lund, R.; Isolauri, E.; Salminen, S.; Laitinen, K. The impact of probiotic supplementation during pregnancy on DNA methylation of obesity-related genes in mothers and their children. Eur. J. Nutr. 2019, 58, 367–377. [Google Scholar] [CrossRef] [PubMed]
- Liu, T.; Song, X.; An, Y.; Wu, X.; Zhang, W.; Li, J.; Sun, Y.; Jin, G.; Liu, X.; Guo, Z. Lactobacillus rhamnosus GG colonization in early life ameliorates inflammaging of offspring by activating SIRT1/AMPK/PGC-1α pathway. Oxidative Med. Cell. Longev. 2021, 2021, 3328505. [Google Scholar] [CrossRef]
- Khalili, L.; Alipour, B.; Asghari Jafarabadi, M.; Hassanalilou, T.; Mesgari Abbasi, M.; Faraji, I. Probiotic assisted weight management as a main factor for glycemic control in patients with type 2 diabetes: A randomized controlled trial. Diabetol. Metab. Syndr. 2019, 11, 1–9. [Google Scholar] [CrossRef]
- Ducrotté, P.; Sawant, P.; Jayanthi, V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J. Gastroenterol. 2012, 18, 4012. [Google Scholar] [CrossRef]
- Naruszewicz, M.; Johansson, M.-L.; Zapolska-Downar, D.; Bukowska, H. Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am. J. Clin. Nutr. 2002, 76, 1249–1255. [Google Scholar] [CrossRef] [PubMed]
- Everard, A.; Matamoros, S.; Geurts, L.; Delzenne, N.M.; Cani, P.D. Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db/db mice. mBio 2014, 5, e01011–e01014. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.T.; Wesley, R.; Shamburek, R.D.; Pucino, F.; Csako, G. Meta-analysis of natural therapies for hyperlipidemia: Plant sterols and stanols versus policosanol. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2005, 25, 171–183. [Google Scholar] [CrossRef] [PubMed]
- Gouni-Berthold, I.; Berthold, H.K. Policosanol: Clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am. Heart J. 2002, 143, 356–365. [Google Scholar] [CrossRef] [PubMed]
- Arruzazabala, M.L.; Molina, V.; Mas, R.; Fernández, L.; Carbajal, D.; Valdés, S.; Castaño, G. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clin. Exp. Pharmacol. Physiol. 2002, 29, 891–897. [Google Scholar] [CrossRef]
- Castano, G.; Mas, R.; Arruzazabala, M.d.L.; Noa, M.; Illnait, J.; Fernández, J.; Molina, V.; Menéndez, A. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int. J. Clin. Pharmacol. Res. 1999, 19, 105–116. [Google Scholar] [CrossRef] [PubMed]
- Simundic, A.-M.; Bölenius, K.; Cadamuro, J.; Church, S.; Cornes, M.P.; van Dongen-Lases, E.C.; Eker, P.; Erdeljanovic, T.; Grankvist, K.; Guimaraes, J.T. Joint EFLM-COLABIOCLI Recommendation for venous blood sampling: V 1.1, June 2018. Clin. Chem. Lab. Med. 2018, 56, 2015–2038. [Google Scholar] [CrossRef] [PubMed]
- Brizita, D.I.; Nevena, I.D. Precise Nutrition and Metabolic Syndrome, Remodeling the Microbiome with Polyphenols, Probiotics, and Postbiotics. In Advances in Precision Nutrition, Personalization and Healthy Aging; Springer: Cham, Switzerland, 2022; pp. 145–178. [Google Scholar]
- Qiu, X.; Wu, Q.; Li, W.; Tang, K.; Zhang, J. Effects of Lactobacillus supplementation on glycemic and lipid indices in overweight or obese adults: A systematic review and meta-analysis. Clin. Nutr. 2022, 41, 1787–1797. [Google Scholar] [CrossRef]
- Mahdavi, R.; Ghorbani, S.; Alipoor, B.; Panahi, G.; Khodabandehloo, H.; Esfahani, E.N.; Razi, F.; Meshkani, R. Decreased serum level of miR-155 is associated with obesity and its related metabolic traits. Clin. Lab 2018, 64, 77–84. [Google Scholar] [CrossRef]
- Lopez, Y.O.N.; Garufi, G.; Seyhan, A.A. Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes. Mol. Biosyst. 2017, 13, 106–121. [Google Scholar] [CrossRef]
- Karkeni, E.; Astier, J.; Tourniaire, F.; El Abed, M.; Romier, B.; Gouranton, E.; Wan, L.; Borel, P.; Salles, J.; Walrand, S. Obesity-associated inflammation induces microRNA-155 expression in adipocytes and adipose tissue: Outcome on adipocyte function. J. Clin. Endocrinol. Metab. 2016, 101, 1615–1626. [Google Scholar] [CrossRef] [PubMed]
- Algieri, F.; Garrido-Mesa, J.; Vezza, T.; Rodríguez-Sojo, M.J.; Rodríguez-Cabezas, M.E.; Olivares, M.; García, F.; Gálvez, J.; Morón, R.; Rodríguez-Nogales, A. Intestinal anti-inflammatory effects of probiotics in DNBS-colitis via modulation of gut microbiota and microRNAs. Eur. J. Nutr. 2021, 60, 2537–2551. [Google Scholar] [CrossRef] [PubMed]
- Heydari, Z.; Rahaie, M.; Alizadeh, A.M.; Agah, S.; Khalighfard, S.; Bahmani, S. Effects of Lactobacillus acidophilus and Bifidobacterium bifidum probiotics on the expression of microRNAs 135b, 26b, 18a and 155, and their involving genes in mice colon cancer. Probiotics Antimicrob. Proteins 2019, 11, 1155–1162. [Google Scholar] [CrossRef] [PubMed]
- Chen, Z.; Ou, H.; Wu, H.; Wu, P.; Mo, Z. Role of microRNA in the pathogenesis of polycystic ovary syndrome. DNA Cell Biol. 2019, 38, 754–762. [Google Scholar] [CrossRef] [PubMed]
- Sørensen, A.E.; Wissing, M.L.; Salö, S.; Englund, A.L.M.; Dalgaard, L.T. MicroRNAs related to polycystic ovary syndrome (PCOS). Genes 2014, 5, 684–708. [Google Scholar] [CrossRef] [PubMed]
- Cirillo, F.; Catellani, C.; Lazzeroni, P.; Sartori, C.; Nicoli, A.; Amarri, S.; La Sala, G.B.; Street, M.E. MiRNAs regulating insulin sensitivity are dysregulated in polycystic ovary syndrome (PCOS) ovaries and are associated with markers of inflammation and insulin sensitivity. Front. Endocrinol. 2019, 10, 879. [Google Scholar] [CrossRef] [PubMed]
- Calcaterra, V.; Rossi, V.; Massini, G.; Casini, F.; Zuccotti, G.; Fabiano, V. Probiotics and Polycystic Ovary Syndrome: A Perspective for Management in Adolescents with Obesity. Nutrients 2023, 15, 3144. [Google Scholar] [CrossRef]
- Ortiz-Dosal, A.; Rodil-García, P.; Salazar-Olivo, L.A. Circulating microRNAs in human obesity: A systematic review. Biomarkers 2019, 24, 499–509. [Google Scholar] [CrossRef]
- Brandao, B.B.; Guerra, B.A.; Mori, M.A. Shortcuts to a functional adipose tissue: The role of small non-coding RNAs. Redox Biol. 2017, 12, 82–102. [Google Scholar] [CrossRef]
- Ortega, F.J.; Mercader, J.M.; Catalan, V.; Moreno-Navarrete, J.M.; Pueyo, N.; Sabater, M.; Gomez-Ambrosi, J.; Anglada, R.; Fernández-Formoso, J.A.; Ricart, W. Targeting the circulating microRNA signature of obesity. Clin. Chem. 2013, 59, 781–792. [Google Scholar] [CrossRef]
- Rippe, C.; Blimline, M.; Magerko, K.A.; Lawson, B.R.; LaRocca, T.J.; Donato, A.J.; Seals, D.R. MicroRNA changes in human arterial endothelial cells with senescence: Relation to apoptosis, eNOS and inflammation. Exp. Gerontol. 2012, 47, 45–51. [Google Scholar] [CrossRef] [PubMed]
- Schober, A.; Nazari-Jahantigh, M.; Wei, Y.; Bidzhekov, K.; Gremse, F.; Grommes, J.; Megens, R.T.; Heyll, K.; Noels, H.; Hristov, M. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat. Med. 2014, 20, 368–376. [Google Scholar] [CrossRef] [PubMed]
- Fu, T.; Seok, S.; Choi, S.; Huang, Z.; Suino-Powell, K.; Xu, H.E.; Kemper, B.; Kemper, J.K. MicroRNA 34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte fibroblast growth factor 21 signaling and SIRT1 function. Mol. Cell. Biol. 2014, 34, 4130–4142. [Google Scholar] [CrossRef]
- Benderska, N.; Dittrich, A.-L.; Knaup, S.; Rau, T.T.; Neufert, C.; Wach, S.; Fahlbusch, F.B.; Rauh, M.; Wirtz, R.M.; Agaimy, A. miRNA-26b overexpression in ulcerative colitis-associated carcinogenesis. Inflamm. Bowel Dis. 2015, 21, 2039–2051. [Google Scholar] [CrossRef] [PubMed]
- Cristóbal, I.; Manso, R.; Gónzález-Alonso, P.; Madoz-Gúrpide, J.; Rojo, F.; García-Foncillas, J. Clinical Value of miR-26b Discriminating Ulcerative Colitis–associated Colorectal Cancer in the Subgroup of Patients with Metastatic Disease. Inflamm. Bowel Dis. 2015, 21, E24–E25. [Google Scholar] [CrossRef] [PubMed]
- Liu, H.; Chu, W.; Gong, L.; Gao, X.; Wang, W. MicroRNA-26b is upregulated in a double transgenic mouse model of Alzheimer’s disease and promotes the expression of amyloid-β by targeting insulin-like growth factor 1. Mol. Med. Rep. 2016, 13, 2809–2814. [Google Scholar] [CrossRef] [PubMed]
- Xu, G.; Ji, C.; Song, G.; Zhao, C.; Shi, C.; Song, L.; Chen, L.; Yang, L.; Huang, F.; Pang, L. MiR-26b modulates insulin sensitivity in adipocytes by interrupting the PTEN/PI3K/AKT pathway. Int. J. Obes. 2015, 39, 1523–1530. [Google Scholar] [CrossRef]
- Acharya, A.; Berry, D.C.; Zhang, H.; Jiang, Y.; Jones, B.T.; Hammer, R.E.; Graff, J.M.; Mendell, J.T. miR-26 suppresses adipocyte progenitor differentiation and fat production by targeting Fbxl19. Genes Dev. 2019, 33, 1367–1380. [Google Scholar] [CrossRef]
- Xu, G.; Ji, C.; Shi, C.; Fu, H.; Zhu, L.; Zhu, L.; Xu, L.; Chen, L.; Feng, Y.; Zhao, Y. Modulation of hsa-miR-26b levels following adipokine stimulation. Mol. Biol. Rep. 2013, 40, 3577–3582. [Google Scholar] [CrossRef]
- Ng, R.; Wu, H.; Xiao, H.; Chen, X.; Willenbring, H.; Steer, C.J.; Song, G. Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology 2014, 60, 554–564. [Google Scholar] [CrossRef]
- Nunez Lopez, Y.O.; Garufi, G.; Pasarica, M.; Seyhan, A.A. Elevated and correlated expressions of miR-24, miR-30d, miR-146a, and SFRP-4 in human abdominal adipose tissue play a role in adiposity and insulin resistance. Int. J. Endocrinol. 2018, 2018, 7351902. [Google Scholar] [CrossRef] [PubMed]
- Zhang, B.; Xing, L.; Wang, B. Dysregulation of circulating miR-24-3p in children with obesity and its predictive value for metabolic syndrome. Obes. Facts 2021, 14, 456–462. [Google Scholar] [CrossRef] [PubMed]
- Ren, K.; Zhu, X.; Zheng, Z.; Mo, Z.-C.; Peng, X.-S.; Zeng, Y.-Z.; Ou, H.-X.; Zhang, Q.-H.; Qi, H.-Z.; Zhao, G.-J. MicroRNA-24 aggravates atherosclerosis by inhibiting selective lipid uptake from HDL cholesterol via the post-transcriptional repression of scavenger receptor class B type I. Atherosclerosis 2018, 270, 57–67. [Google Scholar] [CrossRef] [PubMed]
- Zillikens, M.C.; van Meurs, J.B.; Rivadeneira, F.; Amin, N.; Hofman, A.; Oostra, B.A.; Sijbrands, E.J.; Witteman, J.C.; Pols, H.A.; van Duijn, C.M. SIRT1 genetic variation is related to BMI and risk of obesity. Diabetes 2009, 58, 2828–2834. [Google Scholar] [CrossRef]
- Wellman, A.S.; Metukuri, M.R.; Kazgan, N.; Xu, X.; Xu, Q.; Ren, N.S.; Czopik, A.; Shanahan, M.T.; Kang, A.; Chen, W. Intestinal epithelial sirtuin 1 regulates intestinal inflammation during aging in mice by altering the intestinal microbiota. Gastroenterology 2017, 153, 772–786. [Google Scholar] [CrossRef] [PubMed]
- Hotamisligil, G.S.; Arner, P.; Caro, J.F.; Atkinson, R.L.; Spiegelman, B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Investig. 1995, 95, 2409–2415. [Google Scholar] [CrossRef] [PubMed]
- Tzanavari, T.; Giannogonas, P.; Karalis, K.P. TNF-α and obesity. TNF Pathophysiol. 2010, 11, 145–156. [Google Scholar]
- Lee, I.-K. The role of pyruvate dehydrogenase kinase in diabetes and obesity. Diabetes Metab. J. 2014, 38, 181–186. [Google Scholar] [CrossRef]
Group | Processed Foods | Fruits and Vegetables | Meat | Fish | Dairy Products | Grain Products | Sweets | Physical Activity | Exercise |
---|---|---|---|---|---|---|---|---|---|
Intervention group (N = 12) | Rarely (58.33%) | Every day (75%) | 1–6 p/w (75%) | Rarely (41.67%) 1 p/w (41.67%) | Occasionally (54.55%) | Rarely (60%) | 1–3 p/w (66.67%) | 2–5/w (58.33%) | Rarely (66.67%) |
Placebo group (N = 8) | Rarely (50%) | Every day (87.5%) | 1–6 p/w(50%) | Rarely (37.5%) 1 p/w (37.5%) | Every day (66.67%) | Rarely (50%) | 1–3 p/w (50%) | 6–7/w (62.5%) | Rarely (87.5%) |
T0 | T1 | Level of Changes within the Group † Δ (%) | ||||
---|---|---|---|---|---|---|
Parameter | Intervention Group (N = 12) | Placebo Group (N = 8) | Intervention Group (N = 12) | Placebo Group (N = 8) | Intervention Group (N = 12) | Placebo Group (N = 8) |
Weight (kg) | 97.76 ± 13.47 | 104.86 ± 15.94 | 95.20 ± 14.46 | 101.88 ± 14.11 | −2.67 ± 5.07 | −2.64 ± 4.28 |
p = 0.297, Part. Eta2 = 0.06 | p = 0.321, Part. Eta2 = 0.055 | p = 0.987 | ||||
BMI (kg/m²) | 35.3 ± 5.10 | 39.6 ± 8.14 | 34.39 ± 5.72 | 38.5 ± 7.36 | −2.76 ± 4.99 | −2.55 ± 4.47 |
p = 0.162, Part. Eta2 = 0.106 | p = 0.177, Part. Eta2 = 0.099 | p = 0.926 | ||||
Body fat mass (%) | 42.34 ± 5.44 | 45.53 ± 4.39 | 42.06 ± 4.78 | 45.79 ± 5.51 | −0.4 ± 4.85 | 0.45 ± 5.2 |
p = 0.198, Part. Eta2 = 0.101 | p = 0.144, Part. Eta2 = 0.129 | p = 0.725 |
T0 | T1 | Level of Changes within the Group † Δ (%) | ||||
---|---|---|---|---|---|---|
Parameter | Intervention Group (N = 12) | Placebo Group (N = 8) | Intervention Group (N = 12) | Placebo Group (N = 8) | Intervention Group (N = 12) | Placebo Group (N = 8) |
TC (mg/dL) | 5.27 ± 1.06 | 4.9 ± 0.83 | 6.013 ± 1.64 | 4.70 ± 0.33 | 4.50 ± 9.79 | 1.08 ± 12.93 |
p = 0.440, Part. Eta2 = 0.038 | p = 0.079, Part. Eta2 = 0.218 | p = 0.570 | ||||
HDL (mg/dL) | 1.23 ± 0.32 | 1.25 ± 0.32 | 1.28 ± 0.47 | 1.35 ± 0.44 | 4.63 ± 13.19 | 2.54 ± 10.84 |
p = 0.889, Part. Eta2 = 0.001 | p = 0.783, Part. Eta2 = 0.006 | p = 0.763 | ||||
LDL (mg/dL) | 3.54 ± 1.02 | 2.98 ± 0.75 | 3.91 ± 0.98 | 2.87 ± 0.67 | 4.17 ± 13.06 | 2.09 ± 20.40 |
p = 0.237, Part. Eta2 = 0.092 | p = 0.051, Part. Eta2 = 0.304 | p = 0.832 | ||||
TG (mg/dL) | 1.88 ± 1.15 | 1.46 ± 0.9 | 1.50 ± 0.62 | 1.07 ± 0.24 | 3.54 ± 61.32 | 3.34 ± 41.84 |
p = 0.426, Part. Eta2 = 0.043 | p = 0.131, Part. Eta2 = 0.166 | p = 0.991 |
T0 | T1 | |||
---|---|---|---|---|
Parameter | Intervention Group (N = 12) Δct | Placebo Group (N = 8) Δct | Intervention Group (N = 12) Δct | Placebo Group (N = 8) Δct |
miR-34a-5p | 11.34 ± 1.20 | 11.46 ± 1.55 | 11.97 ± 2.42 | 11.01 ± 1.32 |
p = 0.889, Part. Eta2 = 0.002 | p = 0.356, Part. Eta2 = 0.057 | |||
miR-155-5p | 8.69 ± 1.31 | 9.15 ± 1.13 | 9.3 ± 0.85 * | 8.38 ± 1.06 |
p = 0.425, Part. Eta2 = 0.036 | p = 0.050, Part. Eta2 = 0.205 | |||
miR-125b-5p | 5.41 ± 1.18 | 6.43 ± 1.11 | 5.99 ± 1.36 * | 5.85 ± 1.02 |
p = 0.068, Part. Eta2 = 0.173 | p = 0.805, Part. Eta2 = 0.003 | |||
miR-26b-5p | 1.51 ± 0.44 | 2.17 ± 0.63 | 1.84 ± 0.53 | 1.92 ± 0.35 |
p = 0.013, Part. Eta2 = 0.295 | p = 0.720, Part. Eta2 = 0.007 | |||
miR-126-3p | 1.88 ± 0.56 | 2.42 ± 0.60 | 2.26 ± 0.65 | 2.13 ± 0.55 * |
p = 0.059, Part. Eta2 = 0.184 | p = 0.651, Part. Eta2 = 0.012 | |||
miR-24-3p | 3.13 ± 0.76 | 3.63 ± 1.1 | 3.42 ± 0.38 | 2.71 ± 0.97 |
p = 0.247, Part. Eta2 = 0.074 | p = 0.031, Part. Eta2 = 0.233 | |||
PDK4 | 11.2 ± 0.74 | 11.18 ± 0.47 | 11.00 ± 0.67 | 10.97 ± 0.58 |
p = 0.957, Part. Eta2 = 0.00 | p = 0.916, Part. Eta2 = 0.001 | |||
SIRT1 | 10.10 ± 0.87 | 10.12 ± 0.48 | 10.52 ± 0.63 | 10.38 ± 0.52 * |
p = 0.915, Part. Eta2 = 0.001 | p = 0.635, Part. Eta2 = 0.014 | |||
TNF-α | 10.24 ± 1.66 | 10.46 ± 0.94 | 11.36 ± 1.12 * | 10.89 ± 0.82 |
p = 0.754, Part. Eta2 = 0.007 | p = 0.341, Part. Eta2 = 0.057 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Okuka, N.; Schuh, V.; Krammer, U.; Polovina, S.; Sumarac-Dumanovic, M.; Milinkovic, N.; Velickovic, K.; Djordjevic, B.; Haslberger, A.; Ivanovic, N.D. Epigenetic Aspects of a New Probiotic Concept—A Pilot Study. Life 2023, 13, 1912. https://doi.org/10.3390/life13091912
Okuka N, Schuh V, Krammer U, Polovina S, Sumarac-Dumanovic M, Milinkovic N, Velickovic K, Djordjevic B, Haslberger A, Ivanovic ND. Epigenetic Aspects of a New Probiotic Concept—A Pilot Study. Life. 2023; 13(9):1912. https://doi.org/10.3390/life13091912
Chicago/Turabian StyleOkuka, Nina, Verena Schuh, Ulrike Krammer, Snezana Polovina, Mirjana Sumarac-Dumanovic, Neda Milinkovic, Ksenija Velickovic, Brizita Djordjevic, Alexander Haslberger, and Nevena Dj. Ivanovic. 2023. "Epigenetic Aspects of a New Probiotic Concept—A Pilot Study" Life 13, no. 9: 1912. https://doi.org/10.3390/life13091912